We offer innovative products and services for the management of chronic pulmonary diseases such as Asthma, COPD, Cystic Fibrosis and Pulmonary Hypertension that help improve patient and hospital outcomes.
Despite new medications, little progress has been made in developing new diagnostic and monitoring technologies for respiratory diseases such as asthma. Today’s standard of care is characterized by products, technologies and procedures that have not changed significantly in decades — such as spirometers. These technologies offer little insight for clinicians to make better clinical decisions for their patients in terms of initial diagnosis and continuous monitoring of asthmatic conditions. In terms of diagnosis of asthma, large numbers of asthmatics go untreated: 50% of children, and 33% of adults.
FeNO testing identifies airway inflammation severity
Airway inflammation severity by method of assessment (1)
1. LaForce C, et al. Ann Allergy Asthma Immunol. 2014;113(6):619–623.
The FenomPRO™ point-of-care breath analyzer measures Fractional Exhaled Nitric Oxide (FeNO) molecules. FeNO is an objective biomarker of allergic airway inflammation, an indicator of asthma and other pulmonary conditions. FeNO testing is recommended in the ATS guidelines. Accurate measurement of FeNO levels helps healthcare professionals to correctly titrate medicines and adjust treatments to reduce exacerbations – providing better overall care to their patients.